Caroline M Weipert
Overview
Explore the profile of Caroline M Weipert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
194
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lloyd M, Brett J, Carmeli A, Weipert C, Zhang N, Yu J, et al.
NEJM Evid
. 2024 May;
3(5):EVIDoa2300231.
PMID: 38815172
Background: In estrogen receptor-positive metastatic breast cancer, mutations (ESR1) are a common mechanism of acquired resistance to aromatase inhibitors (ArIh). However, the impact alterations have on CDK4/6 inhibitor (CDK4/6i) sensitivity...
2.
Barzi A, Weipert C, Espenschied C, Raymond V, Wang-Gillam A, Nezami M, et al.
Front Oncol
. 2024 Feb;
14:1339302.
PMID: 38406801
Purpose: Despite accumulating data regarding the genomic landscape of pancreatic ductal adenocarcinoma (PDAC), olaparib is the only biomarker-driven FDA-approved targeted therapy with a PDAC-specific approval. Treating (HER2)-amplified PDAC with anti-HER2...
3.
Franses J, Lim M, Burgoyne A, Mody K, Lennerz J, Chang J, et al.
Oncologist
. 2022 Sep;
27(11):e908-e911.
PMID: 36103364
Advanced hepatocellular carcinoma (HCC) is responsive to immune checkpoint inhibitors, but there are currently no known biomarkers to predict treatment benefit. Blood TMB (bTMB) estimation via circulating tumor DNA (ctDNA)...
4.
Riess J, Reckamp K, Frankel P, Longmate J, Kelly K, Gandara D, et al.
Clin Lung Cancer
. 2021 Jun;
22(6):541-548.
PMID: 34140248
Background: Onalespib is a novel heat shock protein 90 inhibitor (HSP90i). Previous preclinical and clinical studies with HSP90i have demonstrated activity in EGFR-mutant non-small cell lung cancer (NSCLC). This study...
5.
Barzi A, Weipert C, Espenschied C, Lenz H
J Adolesc Young Adult Oncol
. 2020 Sep;
10(3):336-341.
PMID: 32915106
We present the first analysis examining molecular alterations detected utilizing a clinically available cell-free circulating tumor DNA (cfDNA) assay in a cohort of patients with advanced colorectal cancer (aCRC) diagnosed...
6.
Reckamp K, Patil T, Kirtane K, Rich T, Espenschied C, Weipert C, et al.
Clin Lung Cancer
. 2020 Jul;
21(6):545-552.e1.
PMID: 32665165
Background: Outcomes of therapy targeting molecular driver alterations detected in advanced non-small-cell lung (NSCLC) using circulating tumor DNA (ctDNA) have not been widely reported in patients who are targeted therapy-naive....
7.
Panou V, Gadiraju M, Wolin A, Weipert C, Skarda E, Husain A, et al.
J Clin Oncol
. 2018 Aug;
36(28):2863-2871.
PMID: 30113886
Purpose: The aim of the current study was to determine the prevalence and clinical predictors of germline cancer susceptibility mutations in patients with malignant mesothelioma (MM). Methods: We performed targeted...
8.
West A, Blazer K, Stoll J, Jones M, Weipert C, Nielsen S, et al.
Fam Cancer
. 2018 Feb;
17(4):495-505.
PMID: 29445900
Comprehensive genomic cancer risk assessment (GCRA) helps patients, family members, and providers make informed choices about cancer screening, surgical and chemotherapeutic risk reduction, and genetically targeted cancer therapies. The increasing...
9.
Drazer M, Kadri S, Sukhanova M, Patil S, West A, Feurstein S, et al.
Blood Adv
. 2018 Jan;
2(2):146-150.
PMID: 29365323
Next-generation sequencing (NGS)-based targeted gene capture panels are used to profile hematopoietic malignancies to guide prognostication and treatment decisions. Because these panels include genes associated with hereditary hematopoietic malignancies (HHMs),...
10.
Weipert C, Ryan K, Everett J, Yashar B, Chinnaiyan A, Roberts J, et al.
J Genet Couns
. 2017 Aug;
27(1):187-196.
PMID: 28840409
The amount of information produced by genomic sequencing is vast, technically complicated, and can be difficult to interpret. Appropriately tailoring genomic information for non-geneticists is an essential next step in...